

# United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/991,714	11/26/2001	Timothy Elliot Trigg	47-163	4005
75	90 03/11/2003			
NIXON & VA	NDERHYE P.C.	EXAMINER		
8th Floor		AUDET, MAURY A		
1100 North Gle				
Arlington, VA 22201-4714			ART UNIT	PAPER NUMBER
		1654		
		DATE MAIL ED: 03/11/2003		

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No	D	Applicant(s)				
Office Author Occurrence	09/991,714		TRIGG ET AL.				
Office Action Summary	Examiner		Art Unit				
TI MAN INO DATE At this constitution of the same in th	Maury Audet	ar about with the	1654	dross			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply							
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).  - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).							
Status							
1)⊠ Responsive to communication(s) filed on <u>26 /</u> 2a)□ This action is <b>FINAL</b> . 2b)⊠ Th	is action is non						
			prosecution as to t	he merits is			
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213. Disposition of Claims							
4) Claim(s) 17-30 is/are pending in the application.							
4a) Of the above claim(s) is/are withdrawn from consideration.							
5) Claim(s) is/are allowed.							
6)⊠ Claim(s) is/are rejected.							
7) Claim(s) is/are objected to.							
8) Claim(s) <u>17-30</u> are subject to restriction and/or	r election requir	ement.					
Application Papers							
9) The specification is objected to by the Examiner.							
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.							
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner.  If approved; corrected drawings are required in reply to this Office action.							
12) The oath or declaration is objected to by the Examiner.							
Priority under 35 U.S.C. §§ 119 and 120							
13)⊠ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).							
a) All b) Some * c) None of:							
1. Certified copies of the priority documents have been received.							
2. Certified copies of the priority documents have been received in Application No							
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).  * See the attached detailed Office action for a list of the certified copies not received.							
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).							
a) The translation of the foreign language provisional application has been received.							
15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.							
Attachment(s)		_	_				
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s)	4) ( 5) [ 6) [	Notice of Informa	ary (PTO-413) Paper N al Patent Application (P				

Application/Control Number: 09/991,714

Art Unit: 1654

#### **DETAILED ACTION**

# Restriction/Election

1. Restriction to one of the following inventions is required under 35 U.S.C. 121:

In accordance with 37 CFR 1.142, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

- Claims 17-22, drawn to a composition comprising at least one peptide, classified in class 514, subclass 2.
- II. Claims 23-25, and 27, drawn to a process of treating a disease benefited by sex hormone suppression, classified in class 424, subclass 1.45.
- III. Claim 26, drawn to a process of preventing pregnancy, classified in class 424, subclass 811.
- IV. Claim 28-30, drawn to a process of treating a benign prostatic hyperplasia, classified in class 514, subclass 810.

The inventions are distinct, each from the other because of the following reasons:

Inventions I and II are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the product can be used in the materially different process of Invention III.

Inventions I and III are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the

Application/Control Number: 09/991,714

Art Unit: 1654

product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the product can be used in the materially different process of Invention IV.

Inventions I and IV are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the product can be used in the materially different process of Invention II.

Inventions II-IV are related in that each process uses the composition of Invention I.

However, the steps and results of Inventions II-IV are wholly different from each other.

Therefore, the processes employed and goals of Inventions II-IV render each Invention patentably distinct.

## **Requirement for Species Restriction**

- 2. This application contains claims directed to the following patentably distinct species of the claimed invention:
- a) Claims 24:. a specific species from the 11 diseases or conditions.
- b) Claims 17-22: a specific compound species, with % weights and specific compound directed to GnRH, lecithin, and stearin.

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species (that clearly delineates a searchable, chemical structure representing the elected invention/composition) for

Art Unit: 1654

prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, claim 1 is generic.

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

## **Request for Preliminary Set of Amended Claims**

3. As part of the election, Applicant is requested to submit a preliminary set of amended claims, directed to the elected invention, which do not contain any dependencies to any other non-elected inventions (claims) or improper multiple dependent claims, and which are fully descriptive of and include all limitations to that set of claims representing the elected invention.

Art Unit: 1654

#### Conclusion

4. The several inventions above are independent and distinct, each from the other. They have acquired a separate status in the art as a separate subject for inventive effect and require independent searches. The search for each of the above inventions is not co-extensive particularly with regard to the literature search. Further, a reference, which would anticipate the invention of one group, would not necessarily anticipate or even make obvious another group. Finally, the consideration for patentability is different in each case. Thus, it would be an undue burden to examine all of the above inventions in one application. Restriction for examination purposes is therefore proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CRF 1.143).

Applicant is reminded that upon cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Maury Audet whose telephone number is 703-305-5039. The examiner can normally be reached from 7:00 AM - 5:30 PM, off Fridays.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Brenda Brumback can be reached at 703-306-3220. The fax phone numbers for the organization where this application or proceeding is assigned are 703-308-4242 for regular communications and 703-308-1234 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-1235.

MA March 4, 2002

> MICHAEL V. MELLER PATENT EXAMINER